Factor 5 leiden gene mutation in endometrium cancer

Temel Bulgular & Veri:GEREÇ VE YÖNTEM: Selçuk Üniversitesi Meram Tıp Fa kül te - si ne benzer şikayetlerle (postmenopozal kanama ve disfonksiyonel uterin kanama) başvuran toplam 216 hasta çalışmaya dahil edildi.

💡

Sonuç & Katkı:BULGULAR: Her iki grup arasında factor 5 Leiden mutasyon sıklığı açısından istatistiki olarak anlamlı fark bulunmadı (p=0.743).

🔬Tür:Araştırma Makalesi

📍Kapsam:216 hasta

⚙️Değişkenler:Alan Parametreleri

Özet

AMAÇ: Endometriyum kanserli hastalarda faktör 5 Leiden gen (G1691A, A4070G, A5279G bölgeleri) mutasyon sıklığını araştırmak. GEREÇ VE YÖNTEM: Selçuk Üniversitesi Meram Tıp Fa kül te - si ne benzer şikayetlerle (postmenopozal kanama ve disfonksiyonel uterin kanama) başvuran toplam 216 hasta çalışmaya dahil edildi. Hastalar iki gruba ayrıldı. Ilk grupta, endometrioid tipte adenokarsinomu olan 105 hasta, ikinci grupta endometriyal patoloji sonucu benign olan 111 kontrol hastası yer aldı. Her iki grup, factor 5 Ledien genine ait mutasyon sıklıkları (G1691A, A4070G, A5279G bölgeleri) açısından kıyaslandı. BULGULAR: Her iki grup arasında factor 5 Leiden mutasyon sıklığı açısından istatistiki olarak anlamlı fark bulunmadı (p=0.743). SONUÇ: Faktör 5 Leiden mutasyonu ile endometriyum kanseri arasında ilişki bulunamamıştır.

Abstract

OBJECTIVE: In this study, our aim was to investigate the frequency of mutations on factor 5 Leiden gene (G1691A, A4070G, A5279G loci) in endometrial cancer patients. STUDY DESING: 216 patients who admitted to Selcuk University Meram Faculty of Medicine Obstetrics and Gynecology Department with similar complaints (such as postmenopausal bleeding and dysfunctional uterine bleeding) were included in the study. Patients were divided into 2 groups. In the 1st group, there were 105 endometrioid type endometrial adenocarcinoma patients and in the second group, there were 111 patients whose endometrial pathology reported as benign. Two groups are compared according to frequency of mutations on factor 5 Leiden gene (especially G1691A, A4070G, A5279G loci). RESULTS: There were not any statistically significant differences between groups according to frequency of mutations on factor 5 Leiden gene (p=0.743). CONCLUSION: There is no correlation between mutations of factor 5 Leiden gene with endometrial cancer

🔖

Bu Makaleye Atıf Yap

KARATAYLI, R., ÖZDEMİR, S., ÇELİK, Ç., BALCI, O., NERGİS, S., ACAR, H. (2010). Factor 5 leiden gene mutation in endometrium cancer. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 16 - Sayı: 3, 173–177. https://ajindex.com/articles/219650

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries Se, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistant activation of the coagulant pathway. J Thromb Haemost, 2004;2:210714
Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Germ line polymorphisms in cytochrome- P450 1A1 (C4887 CYP1A1) and methylenetetrahidrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis,1997;18:2307-11
Paynter RA, Hankinson SE, Hunter DJ, De Vivo I. No association between MTHFR C->T or 1298 A->C polymorphisms and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev,2004;13:1088-9
Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. Methylenetetrahidrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res,1997;57:1098-102
Kim YI.Methylenetetrahidrofolate reductase polymorphisms, folate and cancer risk: a paradigm of gene-nutrient interactions in carcinogenesis. Nutr Rev, 2000;8:205-9
Hekim N, Ergen A, Yaylım İ, Yılmaz H, Zeybek Ü, Öz - türk O, İsbir T. No association between methylenetetrahidrofolate reductase C677T polymorphism and breast cancer. Cell Biochem Funct,2007;25:115-7
Gershoni- Baruch R, Dagan E, İsraeli D, Kasinetz L, Kadouri E, Friedman E. Association of the C677T polymorphism in the MTHFR gene with breast and /or ovarian cancer risk in Jewish women. Eur Cancer,2000;36:2313-6
Reljic A, Simundic A, Topic E, Nikolac N, Justinic D, Stefanovic M. The methylenetetrahidrofolate reductase (MTHFR) C677T polymorphism and cancer rısk: The Croatian case-control study. Clinical Biochemistry, 2007; 40:981-5
Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ. Polymorphisms in the methylenetetrahidrofolate reductase gene and prostate cancer risk. Int J Oncol, 2004; 25:1465-71
Zeybek U, Yaylım I, Yılmaz H, Agachan B, Ergen A, Arikan S, Bayrak S, Isbir T. The methylenetetrahidrofolate reductase (MTHFR) C677T polymorphism in patıents with gastric and colorectal cancer. Cell Biochem Funct, 2007;25:419-22
Miao X, Xing D, Tan W, Qi j, Lu W, Lin D. Susceptibilility to gastric cardia adenocarcinoma and genetic polymorphisms in methylenetetrahidrofolate reductase in an at risk Chinese population. Cancer Epidemiol Biomark prev, 2002; 11:1454-8
Shen H, Xu Y, Zheng Y, Qian Y, Yu R, Qin Y, Wang X, Spitz MR, Wei Q. Polymorphisms of 5,10 methylenetetr